Revive Therapeutics Announces Proposed Private Pla...
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is proposing to arrange a private placement offering of up to 30,952,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of up to $650,000, and to settle $67,400 owing pursuant to an arm's length note payable by the issuance of 3,209,523 units, at a price of $0.021 per unit, being the same issue price and security being offering pursuant to the private placement.Each unit will consist of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to acquire one common share at an exercise price of $0.05 for a period of 36 months following the closing. The issue price per unit is based upon the 20-day VWAP of the shares traded on the CSE at the time that the Company obtained price protection.The gross proceeds from the private placement offering will be used for working capital and payment of certain trade payables. The proposed private placement may close in one or more tranches.The Company ...Full story available on Benzinga.com
Revive Therapeutics Ltd., a life sciences company focused on developing new treatments for serious medical conditions, has announced plans to raise capital through a private placement and settle an existing debt. The company, trading on the OTCQB (RVVTF), CSE (RVV), and Frankfurt (31R) exchanges, aims to secure up to $650,000 through the private placement offering.
According to the announcement, Revive proposes to offer up to 30,952,381 units at a price of $0.021 per unit. Each unit will consist of one common share of the company and one common share purchase warrant. These warrants will allow the holder to purchase an additional common share at a price of $0.05 within a 36-month period after the deal closes. The price of $0.021 per unit was determined based on the volume-weighted average price (VWAP) of the company's shares on the CSE over the 20 trading days prior to securing price protection.
In addition to the private placement, Revive intends to settle a debt of $67,400 owed under an existing note payable. This settlement will be achieved by issuing 3,209,523 units to the creditor, priced at the same $0.021 per unit as the private placement.
The company plans to use the funds raised from the private placement for general working capital and to pay off certain outstanding trade payables. This infusion of capital is expected to support Revive's ongoing research and development efforts in the field of innovative therapeutics.
The proposed private placement is expected to close in one or more stages, or tranches, as the company continues to execute its financial strategy. Further details regarding the offering are available on Benzinga.com.